Immorta Bio Appoints Howard Brooks to Corporate Board of Directors

Immorta Bio Inc. is developing a dual platform approach to target the biology of aging. It's programs include SenoVax™, an immunotherapy designed to remove senescent cells, and StemCellRevivify™, a regenerative platform aimed at restoring healthier, more youthful cellular function.

Howard Brooks brings over 30 years of experience advising healthcare, life sciences, and biotechnology companies in areas such as corporate strategy, financial oversight, capital raising, governance, and business transformation.

During his time at Ernst & Young, he served as Americas Health Sciences Leader and senior client service partner, advising boards and executives at global pharmaceutical, biotech, healthcare, and high-growth companies.

Howard Brooks, as a member of the Board of Directors of Immorta Bio Inc., will provide guidance on governance, corporate strategy, financial matters, and capital-related decisions, while acting in the best interests of the company and its shareholders.

He will also support the company as a strategic ambassador, engaging with investors, partners, and other key stakeholders as it continues to grow and advance its mission.

Howard Brooks has served on several healthcare and nonprofit boards and is a qualified board financial expert with strong experience in governance, audit, and risk oversight.

He is the second external board member of Immorta Bio Inc., alongside Russell Kaufman, who is a venture partner at Pappas Capital and President Emeritus of The Wistar Institute. Before Wistar, Kaufman spent over 25 years at Duke University, where he held senior academic and leadership roles including Professor of Medicine, Chief of Medical Oncology and Transplantation, and Dean of the School of Medicine.

Read More:Jencap Announces Promotion of Kevin Hahn, Jr. to Executive Vice President

"Immorta Bio is addressing aging at its biological roots, which has the potential to change how we think about disease fundamentally," said Howard Brooks. "I am honored to join the Corporate Board and to serve as a fiduciary, strategic advisor, and ambassador for the Company as it advances toward the clinic and builds long–term value for patients and investors. Serving with such high-quality leaders such as Dr. Boris Reznik and supporting Immorta Bio's mission of enhancing healthspan and lifespan is incredibly well aligned with my personal passion."

"Howard's appointment significantly strengthens our Corporate Board at a pivotal moment for the Company," said Boris Reznik, PhD, Chairman & CEO of Immorta Bio. "As we progress toward clinical development while clearing regulatory approvals and future financing milestones, his deep experience in governance, capital markets, and healthcare strategy will be invaluable. Howard understands how to help build durable, clinically focused healthcare companies and his judgment and perspective will support our long term success."

About Immorta Bio

Founded in 2023, Immorta Bio Inc. is a longevity science company focused on treating aging and age related diseases. The company is developing a dual-platform approach that combines removing damaged senescent cells with regenerative therapies to restore healthier, more youthful biological function. Immorta Bio is advancing several programs toward clinical development and continues to expand its intellectual property portfolio.

Read More:Ken Sliter Joins Partner as Director of Client Development – Capital Programs